Company
Celltrion
WatchBiosimilar developer and manufacturer at Songdo, merged with Celltrion Healthcare in 2023. Direct sales subsidiaries across Europe since 2020.
Standing view
The desk's standing view: Celltrion is the Korean biosimilar business that has moved furthest into direct European distribution, and that decision shapes its behaviour with European partners. It no longer needs a European licensee for its main products; it needs European hospital tenders.
For Spanish and European pharma, Celltrion is a competitor in biosimilars and a plausible partner in new biologics. The two relationships have to be managed by different people.
On the desk
Nothing published on Celltrion yet. Sign in and watch it to be told when there is.